Company intelligence / Profile preview
MetiMedi Pharmaceuticals
Uiwang-si, Gyeonggi-do, South Koreametimedi.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Phase 2 trial of OMT‑111/METI‑101 for refractory metastatic colorectal cancer has been successfully processed with the last patient under investigation. The company plans to report results to Korean authorities after analysis. Early data suggest efficacy and safety.
- Therapeutic areas
- OncologyImmunologyNeurology
- Modalities
- Biological products (main focus)Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on MetiMedi Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MetiMedi Pharmaceuticals.